Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.
Sold as Tzield. Every FDA application for this active ingredient.
As of Nov 15, 2026, FDA lists 1 application for Teplizumab-Mzwv (sold as Tzield), first approved Nov 17, 2022, with 2 new uses approved and 1 published complete response letter.
First approved: Nov 17, 2022
Applications: 1
New uses approved: 2
Complete response letters: 1
Medicare spending, 2025: $1.3M
Orphan exclusivity until: Jun 12, 2033
First approved in the EU: Jan 8, 2026
Medicare Spending
CMS Part D and Part B, 2025, before manufacturer rebates; matched by generic name
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient.Drugs@FDA
